hotspot -WSS

hotspot

author：hotspot 2025-09-29 22:36:43 - browse：74757

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： The effects of a landmark ruling on DNA ownership are becoming clearer

WSS

The strategy behind pharma's lawsuits over drug pricing reform

The battle over the Brookhaven Landfill on Long Island

The creative science of coining drug names

Colonoscopy at 40? Study finds a possible benefit

Do masks work? RCTs can't tell us

STAT's guide to the next generation of CAR

hotspot

hotspot

explore

After affirmative action ruling, medical educators look to 'holistic review'

WATCH: Why do fingernails fall off when they're damaged?

How to save PrEP access — and even expand it

AltruBio raises $225 million to develop ulcerative colitis drug

Supreme Court strikes down use of affirmative action

Gene therapy has helped boys walk. Can scientists keep it that way?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Virginia high school admissions case could be legal follow

The strategy behind pharma's lawsuits over drug pricing reform

leisure time

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Ask STAT: What do you want to know about ChatGPT in medicine?

Sepsis can kill a child within hours. Here's how hospitals are fighting back

Crowdfunding for medical bills sidesteps core problem, author says

The story of mRNA: From a loose idea to a tool that may help curb Covid

entertainment

hotspot

entertainment

focus